ClinicalTrials.gov record
Completed Phase 1 Interventional

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT02188264

Public ClinicalTrials.gov record NCT02188264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer

Study identification

NCT ID
NCT02188264
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
40 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 28, 2014
Primary completion
Jan 30, 2017
Completion
Apr 25, 2019
Last update posted
Feb 10, 2025

2014 – 2019

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
University of California Davis Comprehensive Cancer Center Sacramento California 95817
UCHealth University of Colorado Hospital Aurora Colorado 80045
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141
Washington University School of Medicine St Louis Missouri 63110
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02188264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2025 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02188264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →